This document is an investor deck for Cannassure Therapeutics Ltd that provides information about the company. Cannassure is launching an integrated medical cannabis operation including breeding, cultivation, extraction, research and development, and distribution. The company was founded by Solbar Food Technologies, a leading food manufacturer, to utilize its 60 years of industrial expertise. Cannassure has received initial permits and is in the process of constructing growing and extraction facilities. The executive team brings extensive experience in industries such as biotech, food manufacturing, and the military.
Pfizer exists to develop new, safe medicines to treat serious diseases and make them available to those in need. They strive to positively impact global health through philanthropy focused on increasing access to medicines, healthcare services, and capacity building. Currently, Pfizer prioritizes research in immunology, oncology, cardiovascular, neuroscience, and vaccines through small molecules, biologics and vaccines. They have expanded research and manufacturing facilities globally to grow their reputation and market value.
Novartis is planning to launch a new biologic drug called Fareto to treat moderate to severe plaque psoriasis. The summary focuses on four key points:
1. Novartis has identified four strategic drivers called D-TAP (Distributional Excellence, Technology, Acceptable Price, Patients Consumption) to guide decisions for the Fareto launch.
2. The go-to-market strategy involves targeting dermatologists, patients, and pharmacy chains in major cities. Fareto will be positioned as more efficacious and safe than competitors, with value-added services like a mobile app and money-back guarantee.
3. Ensuring proper dosage compliance is critical. Nov
The document outlines Pfizer's vision, mission, values, and strategies. It discusses Pfizer's commitment to improving health and helping patients live longer lives through innovation. It also summarizes Pfizer's key values of integrity, respect, customer focus, community involvement, innovation, teamwork, performance, leadership, and quality.
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
The document provides an overview and investment summary for ZIVO Bioscience, Inc., a company developing products for human and animal health from proprietary algae strains. It summarizes recent research demonstrating the potential benefits of its compounds for immune support, cholesterol balance, and joint health. The company's business model involves validating product applications through research and licensing intellectual property for animal feed ingredients, supplements, and pharmaceuticals. Near-term opportunities focus on products for bovine mastitis and canine osteoarthritis. The summary outlines the company's management team, product development timeline, potential revenue streams, and exit strategies.
Novartis is a large pharmaceutical company headquartered in Switzerland that was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Over the years, Novartis has expanded through acquisitions of companies like Alcon, Hexal, and Fougera to become a leader in pharmaceuticals, eye care, generics, and vaccines. The document provides details on Novartis' products, history, acquisitions, organizational structure, marketing issues, financial performance, and strategy for further growth.
Novartis invested heavily in research and development, spending over $6 billion in 2007 alone. It pursued both internal discovery and external partnerships. Novartis decentralized its research through institutes like NIBR that were given freedom and resources to pursue new ideas. NIBR was reorganized into disease areas and platforms to consolidate operations. Novartis also formed research institutes focused on neglected diseases and established a venture fund to support external innovation. It had over 400 collaborations and alliances to complement internal efforts, gain new technologies, and access new markets. Moving forward, Novartis needed to balance internal and external strategies to develop new drugs and reach the market quickly while maintaining its science-based approach.
Pfizer exists to develop new, safe medicines to treat serious diseases and make them available to those in need. They strive to positively impact global health through philanthropy focused on increasing access to medicines, healthcare services, and capacity building. Currently, Pfizer prioritizes research in immunology, oncology, cardiovascular, neuroscience, and vaccines through small molecules, biologics and vaccines. They have expanded research and manufacturing facilities globally to grow their reputation and market value.
Novartis is planning to launch a new biologic drug called Fareto to treat moderate to severe plaque psoriasis. The summary focuses on four key points:
1. Novartis has identified four strategic drivers called D-TAP (Distributional Excellence, Technology, Acceptable Price, Patients Consumption) to guide decisions for the Fareto launch.
2. The go-to-market strategy involves targeting dermatologists, patients, and pharmacy chains in major cities. Fareto will be positioned as more efficacious and safe than competitors, with value-added services like a mobile app and money-back guarantee.
3. Ensuring proper dosage compliance is critical. Nov
The document outlines Pfizer's vision, mission, values, and strategies. It discusses Pfizer's commitment to improving health and helping patients live longer lives through innovation. It also summarizes Pfizer's key values of integrity, respect, customer focus, community involvement, innovation, teamwork, performance, leadership, and quality.
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
The document provides an overview and investment summary for ZIVO Bioscience, Inc., a company developing products for human and animal health from proprietary algae strains. It summarizes recent research demonstrating the potential benefits of its compounds for immune support, cholesterol balance, and joint health. The company's business model involves validating product applications through research and licensing intellectual property for animal feed ingredients, supplements, and pharmaceuticals. Near-term opportunities focus on products for bovine mastitis and canine osteoarthritis. The summary outlines the company's management team, product development timeline, potential revenue streams, and exit strategies.
Novartis is a large pharmaceutical company headquartered in Switzerland that was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Over the years, Novartis has expanded through acquisitions of companies like Alcon, Hexal, and Fougera to become a leader in pharmaceuticals, eye care, generics, and vaccines. The document provides details on Novartis' products, history, acquisitions, organizational structure, marketing issues, financial performance, and strategy for further growth.
Novartis invested heavily in research and development, spending over $6 billion in 2007 alone. It pursued both internal discovery and external partnerships. Novartis decentralized its research through institutes like NIBR that were given freedom and resources to pursue new ideas. NIBR was reorganized into disease areas and platforms to consolidate operations. Novartis also formed research institutes focused on neglected diseases and established a venture fund to support external innovation. It had over 400 collaborations and alliances to complement internal efforts, gain new technologies, and access new markets. Moving forward, Novartis needed to balance internal and external strategies to develop new drugs and reach the market quickly while maintaining its science-based approach.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Novartis is a global healthcare company based in Basel, Switzerland with over 123,000 employees worldwide. In 2015, Novartis launched the Novartis Access portfolio to increase access to affordable medicines in low- and middle-income countries. Novartis reached about 66 million patients in 2015 through various access initiatives. Novartis is committed to reducing its environmental footprint and set a target to cut greenhouse gas emissions by 30% by 2020 compared to 2010 levels.
The document provides advice and strategies for transformational growth in the pharmaceutical industry. It discusses how the traditional models of blockbuster drugs and generic copies are being disrupted, requiring companies to reinvent themselves. The key strategies suggested include focusing on niche specialty products, branded generics, consumer healthcare, emerging markets, and biotech/diagnostics. The document emphasizes the need to start transforming now through small steps and immediate opportunities. It introduces the advisory team at The Pharma Partners who have deep experience across various areas to help guide strategic transformations.
Shasun Pharmaceuticals is an Indian pharmaceutical company established in 1976. It generates revenue primarily from active pharmaceutical ingredients (API), contract research and medical services (CRAMS), and finished dosage formulations. API contributes 55% of total revenue. The company has a strong presence in North America, Europe, and Japan and is expanding in Korea and Brazil. It has filed several drug master files and has the highest number of manufacturing facilities approved by the USFDA outside of the U.S. CRAMS contributes 45% of consolidated revenue through formulation research and clinical trials. The company is also pursuing biotechnology and filed 15 ANDAs in FY2015. Recent news showed doubled quarterly profits in Q4 FY2015 compared to the
Tefen's Supply Chain Breakfast Meeting - Sun PharmaNir Gallner
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Pankaj Patel holds degrees in pharmacy and pursued further studies in pharmaceutical technology. He is the Chairman and Managing Director of Cadila Healthcare Limited and its subsidiary Zydus Animal Health Limited. He has led the company's acquisitions, received several honors, and helped develop an H1N1 vaccine. His career has been defined by great leadership, visionary strategy, determination, innovation, and a simple approach.
Therapeutic Benefits Of Wyeth To Pfizerritupon gogoi
The acquisition of Wyeth by Pfizer strengthens Pfizer's position in key disease areas like Alzheimer's disease and inflammation. It brings marketed products and pipeline candidates in these areas, though it may not address Pfizer's underlying R&D productivity issues. The merger provides most benefit in Alzheimer's, where the combined company will dominate the pipeline. It also offers opportunities in rheumatoid arthritis through products like Celebrex and Enbrel, and in vaccines and antibiotics through Wyeth's portfolio. However, the pipeline candidates still face high risks of clinical failure.
Best innovative pharmaceuticals firm, 2020..SophiaSmeeth
Century Pharma is a 30-year-old pharmaceutical company based in Gujarat, India that manufactures active pharmaceutical ingredients and engages in biotechnology research. The company was founded in 1982 and is led by CEO Janak Sheth. Century Pharma produces APIs, engages in contract manufacturing and research, and method development. The company is working to develop treatments for conditions like asthma through biotechnology and stem cell research.
The pharmaceutical industry in India is sized at $5 billion currently ranked 4th in terms of volume and 13th in terms of value, growing at an annual rate of 14.3% and expected to reach $25 billion by 2010. There are over 23,000 pharma companies in India but only around 300 operate in the organized sector. Novartis India is a 51% subsidiary of Swiss company Novartis, established in India in 1996. Novartis India's pharmaceuticals business contributes 62% of its sales and it has grown its total income over the years from 2004-2007 but profitability has been impacted by price regulations in India.
Sun Pharmaceutical Industries was founded in 1983 in Kolkata, India by Dilip Shanghvi. It has since grown to become one of the largest pharmaceutical companies in India through strategic acquisitions and a focus on generic drugs. Some key milestones include acquiring Caraco Pharmaceutical Labs in 1997, acquiring a plant in Ohio in 2005, and merging with Ranbaxy Laboratories in 2014. Sun Pharma has a presence across multiple therapeutic areas and geographic regions. It has a market share of 3.2% in India and follows strict regulatory guidelines. With the aging global population and rising incomes, Sun Pharma is well positioned for continued growth in the coming years through synergies from acquisitions and expanding in emerging markets
This investor presentation provides an overview of Sun Pharmaceutical Industries Ltd., including its strategy, history, business operations, research and development, and financials. The company has pursued a strategy of creating sustainable revenue streams through a focus on chronic therapies and cost leadership through vertical integration. It has grown significantly over the past 30 years through numerous acquisitions and a focus on key international markets like the US, Europe, and others. Sun Pharma has a strong presence in India and international generics markets as well as specialized API and finished dosage manufacturing facilities across four continents.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
The document provides information about the 9th Pharmacovigilance Conference to be held on September 2nd, 2015 in Mumbai, India. It discusses key themes that will be covered including legislation, audits, signal detection, patient safety, and the developing regulatory framework. It outlines the agenda with topics such as PV for biologics, challenges in PV lifecycle management, and the necessary shift of sponsors and CROs from adversaries to partners. The conference aims to bring together representatives from the pharmaceutical industry and regulatory bodies to address issues in pharmacovigilance and risk management. It is intended to help attendees expand their knowledge and network with industry leaders.
Hany Waheed Azzam has over 15 years of experience in medical sales and education roles within pharmaceutical companies like Johnson & Johnson and GlaxoSmithKline. He is currently the Education Manager for Johnson & Johnson Diabetes Care Companies in Saudi Arabia and Egypt. In his roles, he has designed and implemented diabetes education strategies, conducted medical training programs, organized speaker events, and maintained key customer relationships. He has a proven track record of exceeding sales targets and introducing new hospital accounts.
Cosmetic product manufacturing in gujaratglobleseo
Retrive Pharma Pvt Ltd is an Indian nutraceutical and Ayurveda company focused on developing unique, high quality products backed by scientific research. The company aims to provide evidence-based nutraceutical products to help address increasing lifestyle diseases in India due to changing diets and more sedentary lives. Retrive has state-of-the-art manufacturing facilities and a wide distribution network across India to make its innovative products accessible nationwide. The company is committed to quality and has a dedicated research and development team to continuously introduce new products.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The document provides details about an in-plant training report submitted by 5 students from Southeast University at ACME Laboratories Ltd. It includes:
1) An introduction to the in-plant training and about ACME Laboratories which produces over 500 pharmaceutical products across various dosage forms and therapeutic categories.
2) Descriptions of the different production units at ACME including the General Unit, Solid Dosage Unit, Cephalosporin Unit, and the BFS, Liquid & Semisolid Unit.
3) Overviews of other departments visited including Quality Assurance, Quality Control, Warehouse, Engineering, and Research & Development.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Novartis is a global healthcare company based in Basel, Switzerland with over 123,000 employees worldwide. In 2015, Novartis launched the Novartis Access portfolio to increase access to affordable medicines in low- and middle-income countries. Novartis reached about 66 million patients in 2015 through various access initiatives. Novartis is committed to reducing its environmental footprint and set a target to cut greenhouse gas emissions by 30% by 2020 compared to 2010 levels.
The document provides advice and strategies for transformational growth in the pharmaceutical industry. It discusses how the traditional models of blockbuster drugs and generic copies are being disrupted, requiring companies to reinvent themselves. The key strategies suggested include focusing on niche specialty products, branded generics, consumer healthcare, emerging markets, and biotech/diagnostics. The document emphasizes the need to start transforming now through small steps and immediate opportunities. It introduces the advisory team at The Pharma Partners who have deep experience across various areas to help guide strategic transformations.
Shasun Pharmaceuticals is an Indian pharmaceutical company established in 1976. It generates revenue primarily from active pharmaceutical ingredients (API), contract research and medical services (CRAMS), and finished dosage formulations. API contributes 55% of total revenue. The company has a strong presence in North America, Europe, and Japan and is expanding in Korea and Brazil. It has filed several drug master files and has the highest number of manufacturing facilities approved by the USFDA outside of the U.S. CRAMS contributes 45% of consolidated revenue through formulation research and clinical trials. The company is also pursuing biotechnology and filed 15 ANDAs in FY2015. Recent news showed doubled quarterly profits in Q4 FY2015 compared to the
Tefen's Supply Chain Breakfast Meeting - Sun PharmaNir Gallner
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Pankaj Patel holds degrees in pharmacy and pursued further studies in pharmaceutical technology. He is the Chairman and Managing Director of Cadila Healthcare Limited and its subsidiary Zydus Animal Health Limited. He has led the company's acquisitions, received several honors, and helped develop an H1N1 vaccine. His career has been defined by great leadership, visionary strategy, determination, innovation, and a simple approach.
Therapeutic Benefits Of Wyeth To Pfizerritupon gogoi
The acquisition of Wyeth by Pfizer strengthens Pfizer's position in key disease areas like Alzheimer's disease and inflammation. It brings marketed products and pipeline candidates in these areas, though it may not address Pfizer's underlying R&D productivity issues. The merger provides most benefit in Alzheimer's, where the combined company will dominate the pipeline. It also offers opportunities in rheumatoid arthritis through products like Celebrex and Enbrel, and in vaccines and antibiotics through Wyeth's portfolio. However, the pipeline candidates still face high risks of clinical failure.
Best innovative pharmaceuticals firm, 2020..SophiaSmeeth
Century Pharma is a 30-year-old pharmaceutical company based in Gujarat, India that manufactures active pharmaceutical ingredients and engages in biotechnology research. The company was founded in 1982 and is led by CEO Janak Sheth. Century Pharma produces APIs, engages in contract manufacturing and research, and method development. The company is working to develop treatments for conditions like asthma through biotechnology and stem cell research.
The pharmaceutical industry in India is sized at $5 billion currently ranked 4th in terms of volume and 13th in terms of value, growing at an annual rate of 14.3% and expected to reach $25 billion by 2010. There are over 23,000 pharma companies in India but only around 300 operate in the organized sector. Novartis India is a 51% subsidiary of Swiss company Novartis, established in India in 1996. Novartis India's pharmaceuticals business contributes 62% of its sales and it has grown its total income over the years from 2004-2007 but profitability has been impacted by price regulations in India.
Sun Pharmaceutical Industries was founded in 1983 in Kolkata, India by Dilip Shanghvi. It has since grown to become one of the largest pharmaceutical companies in India through strategic acquisitions and a focus on generic drugs. Some key milestones include acquiring Caraco Pharmaceutical Labs in 1997, acquiring a plant in Ohio in 2005, and merging with Ranbaxy Laboratories in 2014. Sun Pharma has a presence across multiple therapeutic areas and geographic regions. It has a market share of 3.2% in India and follows strict regulatory guidelines. With the aging global population and rising incomes, Sun Pharma is well positioned for continued growth in the coming years through synergies from acquisitions and expanding in emerging markets
This investor presentation provides an overview of Sun Pharmaceutical Industries Ltd., including its strategy, history, business operations, research and development, and financials. The company has pursued a strategy of creating sustainable revenue streams through a focus on chronic therapies and cost leadership through vertical integration. It has grown significantly over the past 30 years through numerous acquisitions and a focus on key international markets like the US, Europe, and others. Sun Pharma has a strong presence in India and international generics markets as well as specialized API and finished dosage manufacturing facilities across four continents.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
The document provides information about the 9th Pharmacovigilance Conference to be held on September 2nd, 2015 in Mumbai, India. It discusses key themes that will be covered including legislation, audits, signal detection, patient safety, and the developing regulatory framework. It outlines the agenda with topics such as PV for biologics, challenges in PV lifecycle management, and the necessary shift of sponsors and CROs from adversaries to partners. The conference aims to bring together representatives from the pharmaceutical industry and regulatory bodies to address issues in pharmacovigilance and risk management. It is intended to help attendees expand their knowledge and network with industry leaders.
Hany Waheed Azzam has over 15 years of experience in medical sales and education roles within pharmaceutical companies like Johnson & Johnson and GlaxoSmithKline. He is currently the Education Manager for Johnson & Johnson Diabetes Care Companies in Saudi Arabia and Egypt. In his roles, he has designed and implemented diabetes education strategies, conducted medical training programs, organized speaker events, and maintained key customer relationships. He has a proven track record of exceeding sales targets and introducing new hospital accounts.
Cosmetic product manufacturing in gujaratglobleseo
Retrive Pharma Pvt Ltd is an Indian nutraceutical and Ayurveda company focused on developing unique, high quality products backed by scientific research. The company aims to provide evidence-based nutraceutical products to help address increasing lifestyle diseases in India due to changing diets and more sedentary lives. Retrive has state-of-the-art manufacturing facilities and a wide distribution network across India to make its innovative products accessible nationwide. The company is committed to quality and has a dedicated research and development team to continuously introduce new products.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
The document provides details about an in-plant training report submitted by 5 students from Southeast University at ACME Laboratories Ltd. It includes:
1) An introduction to the in-plant training and about ACME Laboratories which produces over 500 pharmaceutical products across various dosage forms and therapeutic categories.
2) Descriptions of the different production units at ACME including the General Unit, Solid Dosage Unit, Cephalosporin Unit, and the BFS, Liquid & Semisolid Unit.
3) Overviews of other departments visited including Quality Assurance, Quality Control, Warehouse, Engineering, and Research & Development.
Cannabis Therapy Corp specializes in proprietary identification, extraction, production, and marketing of pharmaceutical-grade cannabinoids and cannabinoid-containing products for the food science, pharmaceutical, nutritional supplement and nutraceutical industries.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. The Company launched two new clinical trials in 2021. Aptorum’s Smart-ACT™ platform is designed to bring an average of three drug candidates for orphan diseases to clinical trials every 12-18 months. The Company is now preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.
A study on sales and promotion startegies towards Excellent Biotechnologies Muneer Mohammed
Excellent Biotechnologies is a leading biotech company in India that produces enzymes and chemicals. It aims to double its revenues to $50 million by 2020 by focusing on sales and promotion strategies. The biotech industry in India has experienced high growth of over 20% annually due to increasing investments, outsourcing, and government support. The future looks promising for the biotech sector to become a $100 billion industry by 2025.
This document provides information about the 9th Pharmacovigilance conference happening on September 2nd, 2015 in Mumbai, India. It lists the conference organizers, speakers, sponsors, and themes to be discussed. The conference will bring together pharmaceutical and biotech representatives to discuss drug safety, legislation, audits, signal detection and other pharmacovigilance topics. Attendees will include leaders in pharmacovigilance, drug safety, clinical research, and regulatory affairs from various companies. The goal of the event is to help professionals stay up-to-date on best practices and network with others in the industry.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. The Company launched two new clinical trials in 2021. Aptorum’s Smart-ACT™ platform is designed to bring an average of three drug candidates for orphan diseases to clinical trials every 12-18 months. The Company is now preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.
The document summarizes Schering-Plough's acquisition of Organon BioSciences and the promise it offers the combined company. The acquisition created a world-class company in women's health and fertility treatment and strengthened its central nervous system therapies portfolio. It also formed a leading animal health unit. The CEO discusses the challenges of driving innovation for difficult diseases and rising to challenges in health care. He expresses confidence that the combined company can realize its promise to benefit patients and other stakeholders over the long term through continuous transformation.
Regulatory affairs professionals ensure public health by controlling the safety and efficacy of products. They keep track of changing legislation and advise their company on legal and scientific requirements. They collect and evaluate scientific data, present registration documents to regulatory agencies, and obtain marketing authorization for products. A good regulatory affairs professional helps maximize resources and serves as the first point of contact between a company and government authorities.
- Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies for central nervous system indications.
- They are developing novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) for indications like Tourette Syndrome and Mild Cognitive Impairment.
- For Tourette Syndrome, they are combining THC with PEA in a proprietary combination therapy called THX-TS01 that has begun Phase II clinical trials based on a 505(b)(2) regulatory pathway.
- For Mild Cognitive Impairment, they are developing an "Ultra-Low Dose THC" therapy called THX-ULD
Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies developed in Israel, including novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) to treat conditions like Tourette Syndrome and mild cognitive impairment. The company is repurposing dronabinol for new indications by exploring combination therapies based on the "entourage effect" as well as an "ultra-low dose THC" approach for cognitive deterioration and pre-Alzheimer's disease.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
Diplomat Investor day 2017 presentation 6.26.17DiplomatIR
1. The document outlines an agenda for an analyst and investor day presentation by Diplomat Pharmacy Inc.
2. It discusses key topics like drug lifecycle management, pharmaceutical launch strategies, and specialty pharmacy management services.
3. The presentation features several speakers from Diplomat who will cover these topics in more depth.
David Pritchard is a biopharmaceutical executive with extensive experience in business development, M&A, licensing, and strategic advisory services. He has held roles such as CEO, VP of business development, and independent consultant. Through these roles, he has completed numerous transactions involving licensing deals, acquisitions, and fundraising for companies in biopharma. He currently provides strategic and tactical advice to life sciences companies as an independent consultant.
Krishgen is an Indian biotech company established in 2003 that focuses on medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides immunoassay kits, human cell lines, glycobiology tools, and preclinical toxicology products to support research and drug development.
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Similar to Cannassure investors deck feb 2019 (20)
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4